看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯，血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。3 j; z3 M2 |* y/ O ~
( x% ]% J* U4 K! i/ ^, y) v( {! Q# ~* a& W
Currently available feasibility data for possible combination strategies.
1 A0 G# i9 z4 z6 R7 c3 U: U————————————————————————————————( ?- i4 `7 G' ]; |: K, ]' s" `
Combination Feasibility according to preliminary data 9 |. B3 j; w t+ m) [
——————————————————————————————————2 p- W: u* j; _
Bevacizumab + sorafenib Yes, reduced dose
2 R- [* _) a3 IBevacizumab + sunitinib† No 0 S& M. o, a% V9 j$ ]* A" U
Bevacizumab + temsirolimus Yes ( }0 ?. O% u# l) u
Bevacizumab + everolimus Yes
+ b; [7 X5 |% X- U! sSorafenib + sunitinib ?
C1 a8 P7 z" ?* Y0 v0 g# o% mSorafenib + temsirolimus Yes, reduced dose
! Z# c3 P: B# o% Z% c+ `Sorafenib + everolimus Yes, reduced dose : ^, @2 m7 \0 c4 n7 e ]" a
Sunitinib + temsirolimus† No
& t, y* b7 w2 s, {# ]) Y \. BSunitinib + everolimus ?
* w! Y7 h0 J% [8 WTemsirolimus + everolimus ? ' D A" S$ A! U* y( e5 V* h/ D
————————————————————5 @) b" w8 i) Z* K9 G9 ~/ D
†Led to US FDA warning.9 ]$ O2 D$ e! U8 a
?: As yet unattempted combination.
6 p* x# a6 S% j1 n; h |
显身卡
